Sorry, but no relevant information or results could be found for your search.
German biotech Kupando raises €10M more to take its innate immunity drug into the clinic
An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the learned, antibody-generating machinery that checkpoint inhibitors like pembrolizumab […]<br / [...]
What to read this weekend: A brief history of humankind's many apocalypses
These are some recently released titles we think are worth adding to your reading list. This week, we read Apocalypse: How Catastrophe Transformed Our World and Can Forge New Futures, a compelling new history book by science journalist Lizzie Wade, and Behemoth, a riveting mini-series for Dark Horse that explores the classic idea of a kaiju attack from a horrifying... inside perspective. <br /& [...]
